4/3/2013

BioMarin Pharmaceutical filed an application with the U.K. Medicines and Healthcare Products Regulatory Agency seeking approval to initiate a Phase I/II trial of BMN-190, an experimental drug for neuronal ceroid lipofuscinosis type 2, a form of Batten disease. The firm expects patient enrollment for the trial to begin this year.

Related Summaries